RxDoctor Payments Data

Andrew Strand, DO

Ophthalmology · Evansville, INNPI 1295077402

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,687 of the $11,938 with a category attached, or 72.8%. Regeneron Healthcare Solutions, Inc. accounts for 77.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $7,604, more than ten times the $23 reported in 2019. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,938in general payments, 2019–2025

Across 99 payments — averaging $120.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$9K
  • Alimera Sciences, Inc.$707
  • Carl Zeiss Meditec USA, Inc.$617
  • Genentech USA, Inc.$574
  • Alcon$173
  • Astellas Pharma US Inc$95
  • plus $518 from 13 others
$8,549in research payments, 2019–2025

Across 1 payment — averaging $8549.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$9K

What the payments were for

  • Speaking & faculty fees$8,68773%
  • Food & beverage$2,73723%
  • Other$5144%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,938 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$6,705,638
Medicare patients
1,324
Services billed
47,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate244$8,933
Brimonidine Tartrate30$1,543
Ketorolac Tromethamine62$1,355
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,301
Tobramycin151$836
Latanoprost139$799
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$251
Dorzolamide Hcl13$168
Timolol Maleate29$165
Ondansetron OdtOndansetron20$133
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$98

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →